Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucerastat monotherapy in adults with Fabry disease
2017-003369-85Phase 3Unknown
- Sponsor
- Idorsia
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Fabry disease (FD) comparing Lucerastat with Placebo (2 arms). Primary endpoint: Change from baseline to Month 6 in modified BPI-SF item 3 neuropathic pain score. Status: unknown.
02
Drugs
lucerastat
03
Conditions
Fabry disease (FD)
Beyond the preview
Go deeper on 2017-003369-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003369-85.